Publications by authors named "Bruce R Charlesworth"
In phase one of the REALIZE study, zolmitriptan nasal spray demonstrated a significant headache response from 10 min post-dose and total symptom relief from 30 min post-dose. The objective of phase two was to investigate patients' dosing patterns, satisfaction and preference following open-label treatment with the nasal spray. Up to 3 attacks were treated.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the long-term safety and tolerability of zolmitriptan 5 mg nasal spray in treating migraines over a year, focusing on patients mostly new to triptan nasal sprays.
- Adverse events occurred in about 32.8% of migraine treatments, with the most common effects being unusual taste and paresthesia, but these were mostly mild and temporary, declining over time.
- The nasal spray was effective, achieving a 2-hour pain-free rate of 53.8%, especially in patients with milder headache intensity, and the presence of rhinitis had no impact on treatment outcomes.
Objectives: The objective of phase 1 (reported here) of this two-phase study was to assess the efficacy of zolmitriptan 5 mg nasal spray, in terms of ability to provide relief from all migraine symptoms, in a controlled setting, designed to replicate clinical practice.
Background: Zolmitriptan nasal spray has been shown to be fast acting and highly effective in the treatment of migraine, as assessed using standard endpoints, such as headache response and pain-free rates.
Methods: In the double-blind first phase of the study, patients with migraine were randomized to receive zolmitriptan 5 mg nasal spray or placebo to treat a single migraine attack.
Objectives: To primarily assess the tolerability of zolmitriptan (Zomig) nasal spray 5mg in the long-term treatment of migraine, as well as determine efficacy and consistency of effect over time (up to 1 year).
Methods: This randomised, double-blind-to-dose, parallel-group, multicentre study was designed as a two-phase, crossover trial with a total duration of 1 year. In the pre-crossover phase, 1,093 patients aged 18-65 years with an established diagnosis of migraine with or without aura received intranasal zolmitriptan 5, 2.
Objective: Zolmitriptan oral tablet is highly effective and well tolerated in the acute treatment of migraine with and without aura in adults. A nasal spray formulation has now been developed. The objective of this study was to compare the efficacy and tolerability of fixed doses of zolmitriptan administered via a nasal spray with placebo and zolmitriptan oral tablet in the acute treatment of migraine.
View Article and Find Full Text PDF